Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Shareholder Director Nominations
Item 5.08
(a) To the extent applicable, the information contained in Item 8.01 below is incorporated herein by reference.
As previously reported in a Current Report on Form 8-K filed by Amyris, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on May 20, 2019, which disclosure is incorporated herein by reference, on May 14, 2019, the Company’s Board of Directors (the “Board”) scheduled the date of the Company’s 2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”) for August 27, 2019.
On July 23, 2019, the Board re-scheduled the date of the 2019 Annual Meeting for November 19, 2019, which is more than 30 days after the anniversary of the Company’s 2018 Annual Meeting of Stockholders.
In accordance with the Company’s restated bylaws, notice by a stockholder of any qualified stockholder proposal or qualified stockholder nomination (including any notice on Schedule 14N) must be delivered to the Company at its principal executive offices located at 5885 Hollis Street, Suite 100, Emeryville, California 94608, addressed to the Secretary of the Company, by September 5, 2019. Such stockholder proposals or nominations must conform to the rules and regulations promulgated by the SEC and the Company’s restated bylaws. Any such notice received after September 5, 2019 will be considered untimely and not properly brought before the 2019 Annual Meeting.
About Amyris, Inc. (NASDAQ:AMRS)
Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.
